Aligos Therapeutics (ALGS) Enterprise Value (2021 - 2025)
Aligos Therapeutics' Enterprise Value history spans 5 years, with the latest figure at -$77.9 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 110.02% year-over-year to -$77.9 million; the TTM value through Dec 2025 reached -$77.9 million, down 110.02%, while the annual FY2025 figure was -$77.9 million, 110.02% down from the prior year.
- Enterprise Value reached -$77.9 million in Q4 2025 per ALGS's latest filing, down from -$42.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$24.4 million in Q1 2024 to a low of -$242.2 million in Q3 2021.
- Average Enterprise Value over 5 years is -$121.6 million, with a median of -$110.3 million recorded in 2022.
- Peak YoY movement for Enterprise Value: soared 76.46% in 2024, then plummeted 728.98% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$187.0 million in 2021, then skyrocketed by 56.44% to -$81.4 million in 2022, then crashed by 66.74% to -$135.8 million in 2023, then surged by 72.68% to -$37.1 million in 2024, then plummeted by 110.02% to -$77.9 million in 2025.
- Per Business Quant, the three most recent readings for ALGS's Enterprise Value are -$77.9 million (Q4 2025), -$42.1 million (Q3 2025), and -$123.0 million (Q2 2025).